# Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

> **NCT05896748** · PHASE3 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 94 (actual)

## Conditions studied

- Human Immunodeficiency Virus Type 1 (HIV-1)

## Interventions

- **DRUG:** Cabotegravir - Injectable Suspension (CAB LA)
- **DRUG:** Rilpivirine - Injectable Suspension (RPV LA)

## Key facts

- **NCT ID:** NCT05896748
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-08
- **Primary completion:** 2023-09-14
- **Final completion:** 2023-09-14
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2024-11-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05896748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05896748, "Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05896748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*